

Centers for Disease Control and Prevention
(CDC)

National Center for Environmental Health
(NCEH)

Division of Laboratory Sciences (DLS)

**NEWBORN SCREENING AND
MOLECULAR BIOLOGY BRANCH
(NSMBB)**

**NEWBORN SCREENING QUALITY
ASSURANCE PROGRAM (NSQAP)
PORTAL**

CFDNAPT USER GUIDE

July 2026

Table of Contents


- 1. CFDNAPT Program Entry Page.....2
 - 1.1 Navigation.....2
 - 1.2 Primary Method Information.....4
 - 1.3 Secondary/Confirmatory Method Information.....11
 - 1.4 Extraction Method Information.....17
 - 1.5 Specifying Variants Detected.....18
 - 1.6 Specimen Results - Pathogenic Variant Data Entry.....21
 - 1.7 Save.....24
- 2. CFDNAPT Review & Submit Page.....25
 - 2.1 Navigation.....25
 - 2.2 Review.....26
 - 2.3 Submit.....30
 - 2.4 Save Data – PDF Format.....32

1. CFDNAPT Program Entry Page

1.1 Navigation

To enter and save CFDNAPT data, navigate to the CFDNAPT program entry page. Access the page from the 'CFDNA Entry' option on the Molecular PT landing page.

1. Click '**PT Information**' from the upper toolbar.



2. Click '**Molecular PT**' from the PT Information page.



3. Click '**CFDNA**' to navigate to the entry page.

CFDNA Entry		CFDNA Review/Submit		
Name ↑	Saved By	Name ↑	Submitted By	isSubmitted
CFDNA		CFDNA		No

SMA Entry		SMA Review/Submit		
Name	Saved By	Name ↑	Submitted By	isSubmitted
SMA		SMA		No

TREC Entry		TREC Submit/Review		
Name ↑	Saved By	Name ↑	Submitted By	isSubmitted
TREC		TREC		Yes

4. You will be directed to the CFDNA entry page to enter method information and data.

1.2 Primary Method Information

Navigate to the page titled 'Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)' to enter method information including primary method, secondary/confirmatory method, and extraction method. Navigation details can be found in section 1.1.

Home > Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

‡ Definition of commercial kit – A kit that has been designed by the manufacturer to sequence the CFTR gene

Method Information

Primary Method

Select a primary method *

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Was a gene sequencing method used? *

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Extraction Method

Select an extraction method *

1. Click on the magnifying glass to see the primary methods list.

Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Definition of commercial kit – A kit that has been designed by the manufacturer to sequence the CFTR gene

Method Information

Primary Method



Select a primary method *

2. Search for methods using the search box or page numbers.

Lookup records

✓	Name ↑
✓	Abbott Molecular CF Genotyping Assay v3
	Agena Bioscience iPLEX Pro CFTR Panel (72 mutations)
	All other gene sequencing protocols including Sanger and Next Gen
	Allele-specific Oligonucleotide PCR
	Amplification and Polyacrylamide Gel Electrophoresis (PCR-PAGE)
	Amplification and Restriction Fragment Length Polymorphism Analysis (PCR-RFLP)
	Astra Biotech CFcheck DE-31
	Capillary Electrophoresis

3. Choose a primary method then click 'Select'.



- If 'Other' is selected, a text box will appear. You are **required** to specify your primary method details.

Lookup records

other

✓	Name ↑
✓	Other

Select Cancel Remove value

Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Definition of commercial kit – A kit that has been designed by the manufacturer to sequence the CFTR gene

Method Information

Primary Method

Select a primary method *

Other

Other-you must specify *

- Indicate whether your selected primary method is a custom commercial assay, laboratory developed test, or a commercial assay with restrictions set by your lab by clicking the drop-down arrow.

Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Definition of commercial kit – A kit that has been designed by the manufacturer to sequence the CFTR gene

Method Information

Primary Method

Select a primary method *

Abbott Molecular CF Genotyping Assay v3

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

No

6. If no restrictions or laboratory specific customizations were made, no additional information is required.

Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Definition of commercial kit – A kit that has been designed by the manufacturer to sequence the CFTR gene

Method Information

Primary Method

Select a primary method *

Abbott Molecular CF Genotyping Assay v3

✕ 🔍

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

No

Was a gene sequencing method used? *

No

7. If restrictions were placed or laboratory specific customizations were made, you are required to specify the variants detected. See section 1.5 for additional information on a helpful tool for correctly formatting this information.

NOTE: List the variants detected by your lab, separate each variant by a semicolon ";".

If the variants that your lab detect are on your program's website, you may instead reference your website.

Method Information

Primary Method

Select a primary method *

Abbott Molecular CF Genotyping Assay v3

✕ 🔍

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify variants detected: *

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

No

8. Indicate whether a gene sequencing method was used by clicking the drop-down arrow.

Select a primary method *

Abbott Molecular CF Genotyping Assay v3

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify variants detected: *

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.? (c.165-3C>T);297-1G->A | p.? (c.165-1G>A);E56K | p.Glu56Lys (c.166G>A);W57G | p.Trp57Gly

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

No

Secondary/Confirmatory Method

9. If a gene sequencing method was not used, no additional information is required.

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify variants detected: *

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.? (c.165-3C>T);297-1G->A | p.? (c.165-1G>A);E56K | p.Glu56Lys (c.166G>A);W57G | p.Trp57Gly

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

No

Secondary/Confirmatory Method

10. If a gene sequencing method was used, indicate whether a commercial kit was used.

Note: A commercial kit is defined as a kit that has been designed by the manufacturer to sequence the CFTR gene.

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify variants detected: *

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.? (c.165-3C>T);297-1G->A | p.? (c.165-1G>A);E56K | p.Glu56Lys (c.166G>A);W57G | p.Trp57Gly

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Yes

Was a commercial kit used? *

11. If a commercial kit was used, no further information is required.

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify variants detected: *

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.? (c.165-3C>T);297-1G->A | p.? (c.165-1G>A);E56K | p.Glu56Lys (c.166G>A);W57G | p.Trp57Gly

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Yes

Was a commercial kit used? *

Yes

12. If a commercial kit was not used, additional gene sequencing regions information is required.

Specify variants detected: *

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.? (c.165-3C>T);297-1G->A | p.? (c.165-1G>A);E56K | p.Glu56Lys (c.166G>A);W57G | p.Trp57Gly

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Yes

Was a commercial kit used? *

No

For non-commercial kits, provide regions of the gene that are sequenced *

Specify variants detected: *

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.? (c.165-3C>T);297-1G->A | p.? (c.165-1G>A);E56K | p.Glu56Lys (c.166G>A);W57G | p.Trp57Gly

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Yes

Was a commercial kit used? *

No

For non-commercial kits, provide regions of the gene that are sequenced *

exons 1 to 27 and at least 20 bases into the 5' and 3' ends of all introns, the CFTR poly T status and TG tract, intron 22

13. After entering primary method information, continue to the secondary/confirmatory method section (if necessary – section 1.3) or the extraction method section (section 1.4).

1.3 Secondary/Confirmatory Method Information

Navigate to the page titled 'Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)' to enter method information including primary method, secondary/confirmatory method, and extraction method.

Reporting of secondary/confirmatory method information is only required by participants if a secondary/confirmatory method is utilized. If this method is not utilized, proceed to section 1.4 for guidance on reporting extraction method information. If a secondary/confirmatory method is utilized, continue to step 1 for reporting guidance.

1. Select a secondary/confirmatory method by clicking on the magnifying glass.

Was a gene sequencing method used? *

Yes

* Was a commercial kit used? *

No

For non-commercial kits, provide regions of the gene that are sequenced *

exons 1 to 27 and at least 20 bases into the 5' and 3' ends of all introns, the CFTR poly T status and TG tract, intron 22

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Extraction Method

Select an extraction method *

2. Choose a method then click 'Select'.

Lookup records

Search

Name ↑

- Abbott Molecular CF Genotyping Assay v3
- Agena Bioscience iPLEX Pro CFTR Panel (72 mutations)**
- All other gene sequencing protocols including Sanger and Next Gen
- Allele-specific Oligonucleotide PCR
- Amplification and Polyacrylamide Gel Electrophoresis (PCR-PAGE)
- Amplification and Restriction Fragment Length Polymorphism Analysis (PCR-RFLP)
- Astra Biotech CFcheck DE-31
- Capillary Electrophoresis

< 1 2 3 4 >

Select Cancel Remove value

For non-commercial kits, provide regions of the gene that are sequenced *

exons 1 to 27 and at least 20 bases into the 5' and 3' ends of all introns, the CFTR poly T status and TG tract, intron 22

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Agena Bioscience iPLEX Pro CFTR Panel (72 mutations) [X] [Q]

Select an algorithm for utilization of the secondary/confirmatory method *

[Q]

3. Select an algorithm for utilization of the secondary/confirmatory method by clicking on the magnifying glass.

For non-commercial kits, provide regions of the gene that are sequenced *

exons 1 to 27 and at least 20 bases into the 5' and 3' ends of all introns, the CFTR poly T status and TG tract, intron 22

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Agena Bioscience iPLEX Pro CFTR Panel (72 mutations) [X] [Q]

Select an algorithm for utilization of the secondary/confirmatory method *

[Q]

4. Choose an algorithm then click 'Select'.

Lookup records

Search [Q]

✓ Utilization of Secondary Confirmatory ↑

✓ Both the primary and secondary methods are used to detect variants

Other

Secondary method run only when primary method is positive and may find additional variants

Secondary method run only when primary method is positive and only for confirmation (NO new variants identified)

Select Cancel Remove value

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Agena Bioscience iPLEX Pro CFTR Panel (72 mutations)

Select an algorithm for utilization of the secondary/confirmatory method *

Both the primary and secondary methods are used to detect variants

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

- Click the drop-down arrow to indicate whether your selected secondary/confirmatory method is a custom commercial assay, laboratory developed test, or a commercial assay with restrictions set by your lab.

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Agena Bioscience iPLEX Pro CFTR Panel (72 mutations)

Select an algorithm for utilization of the secondary/confirmatory method *

Both the primary and secondary methods are used to detect variants

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

- If no restrictions or laboratory specific customizations were made, no additional information is required.

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Agena Bioscience iPLEX Pro CFTR Panel (72 mutations)

Select an algorithm for utilization of the secondary/confirmatory method *

Both the primary and secondary methods are used to detect variants

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

No

Was a gene sequencing method used? *

- If restrictions were placed or laboratory specific customizations were made, you are required to specify the variants detected. See section 1.5 for additional information on a helpful tool for correctly formatting this information.

NOTE: List the variants detected by your lab, separate each variant by a semicolon ";".

If the variants that your lab detect are on your program's website, you may instead reference your website.

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Agena Bioscience iPLEX Pro CFTR Panel (72 mutations)

Select an algorithm for utilization of the secondary/confirmatory method *

Both the primary and secondary methods are used to detect variants

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify Variants Detected *

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

- Indicate whether a gene sequencing method was used by clicking the drop-down arrow.

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify Variants Detected *

(c.174-177delTGA);S66insA | p.Arg59Lys*10 (c.175dupA);E60K | p.Glu60Lys (c.178G>A);E60X | p.Glu60* (c.178G>T);P67L | p.Pro67Leu (c.200C>T);K75X | p.Arg75* (c.223C>T);365-366insT | p.Trp79Leufs*32 (c.233dupT);G85E | p.Gly85Glu (c.254G>A);394delTT | p.Leu88Ilefs*22 (c.262_263delTT);L88X | p.Leu88* (c.263T>A);L88X | p.Leu88* (c.263T>G);G91R | p.Gly91Arg (c.271G>A);405+1G->A | p.? (c.273+1G>A);405+3A->C | p.? (c.273+3A>C);406-2A->G | p.? (c.274-2A>G);406-1G->A | p.? (c.274-1G>A);E92K | p.Glu92Lys (c.274G>A);E92X | p.Glu92* (c.274G>T);Q98X | p.Gln98* (c.292C>T);Q98R | p.Gln98Arg (c.293A>G);P99L | p.Pro99Leu (c.296C>T);L102R | p.Leu102Arg (c.305T>G);442delA | p.Arg104Glu*3 (c.310delA)

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Extraction Method

Select an extraction method *

9. If a gene sequencing method was not used, no additional information is required.

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify Variants Detected *

(C.174_177delTAGA);306insA | p.Arg59Lys*10 (C.175dupA);E60K | p.Glu60Lys (C.178G>A);E60X | p.Glu60* (C.178G>T);P67L | p.Pro67Leu (C.200C>T);K75X | p.Arg75* (C.223C>T);365-366insT | p.Trp79Leufs*32 (C.233dupT);G85E | p.Gly85Glu (C.254G>A);394delTT | p.Leu88Ilefs*22 (C.262_263delTT);L88X | p.Leu88* (C.263T>A);L88X | p.Leu88* (C.263T>G);G91R | p.Gly91Arg (C.271G>A);405+1G->A | p.? (C.273+1G>A);405+3A->C | p.? (C.273+3A>C);406-2A->G | p.? (C.274-2A>G);406-1G->A | p.? (C.274-1G>A);E92K | p.Glu92Lys (C.274G>A);E92X | p.Glu92* (C.274G>T);Q98X | p.Gln98* (C.292C>T);Q98R | p.Gln98Arg (C.293A>G);P99L | p.Pro99Leu (C.296C>T);L102R | p.Leu102Arg (C.305T>G);442delA | p.Arg104Glu*3 (C.310delA)

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

No

Extraction Method

Select an extraction method *

Q

10. If a gene sequencing method was used, indicate whether a commercial kit was used.

Note: A commercial kit is defined as a kit that has been designed by the manufacturer to sequence the CFTR gene.

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify Variants Detected *

(C.174_177delTAGA);306insA | p.Arg59Lys*10 (C.175dupA);E60K | p.Glu60Lys (C.178G>A);E60X | p.Glu60* (C.178G>T);P67L | p.Pro67Leu (C.200C>T);K75X | p.Arg75* (C.223C>T);365-366insT | p.Trp79Leufs*32 (C.233dupT);G85E | p.Gly85Glu (C.254G>A);394delTT | p.Leu88Ilefs*22 (C.262_263delTT);L88X | p.Leu88* (C.263T>A);L88X | p.Leu88* (C.263T>G);G91R | p.Gly91Arg (C.271G>A);405+1G->A | p.? (C.273+1G>A);405+3A->C | p.? (C.273+3A>C);406-2A->G | p.? (C.274-2A>G);406-1G->A | p.? (C.274-1G>A);E92K | p.Glu92Lys (C.274G>A);E92X | p.Glu92* (C.274G>T);Q98X | p.Gln98* (C.292C>T);Q98R | p.Gln98Arg (C.293A>G);P99L | p.Pro99Leu (C.296C>T);L102R | p.Leu102Arg (C.305T>G);442delA | p.Arg104Glu*3 (C.310delA)

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Yes

Was a commercial kit used? *

Q

11. If a commercial kit was used, no further information is required.

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify Variants Detected *

(c.174_177delTAGA);306insA | p.Arg59Lysfs*10 (c.175dupA);E60K | p.Glu60Lys (c.178G>A);E60X | p.Glu60* (c.178G>T);P67L | p.Pro67Leu (c.200C>T);K75X | p.Arg75* (c.223C>T);365-366insT | p.Trp79Leufs*32 (c.233dupT);G85E | p.Gly85Glu (c.254G>A);394delTT | p.Leu88Ilefs*22 (c.262_263delTT);L88X | p.Leu88* (c.263T>A);L88X | p.Leu88* (c.263T>G);G91R | p.Gly91Arg (c.271G>A);405+1G->A | p.? (c.273+1G>A);405+3A->C | p.? (c.273+3A>C);406-2A->G | p.? (c.274-2A>G);406-1G->A | p.? (c.274-1G>A);E92K | p.Glu92Lys (c.274G>A);E92X | p.Glu92* (c.274G>T);Q98X | p.Gln98* (c.292C>T);Q98R | p.Gln98Arg (c.293A>G);P99L | p.Pro99Leu (c.296C>T);L102R | p.Leu102Arg (c.305T>G);442delA | p.Arg104Glu fs*3 (c.310delA)

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Yes

* Was a commercial kit used? *

Yes

12. If a commercial kit was not used, gene sequencing regions information is required.

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify Variants Detected *

(c.174_177delTAGA);306insA | p.Arg59Lysfs*10 (c.175dupA);E60K | p.Glu60Lys (c.178G>A);E60X | p.Glu60* (c.178G>T);P67L | p.Pro67Leu (c.200C>T);K75X | p.Arg75* (c.223C>T);365-366insT | p.Trp79Leufs*32 (c.233dupT);G85E | p.Gly85Glu (c.254G>A);394delTT | p.Leu88Ilefs*22 (c.262_263delTT);L88X | p.Leu88* (c.263T>A);L88X | p.Leu88* (c.263T>G);G91R | p.Gly91Arg (c.271G>A);405+1G->A | p.? (c.273+1G>A);405+3A->C | p.? (c.273+3A>C);406-2A->G | p.? (c.274-2A>G);406-1G->A | p.? (c.274-1G>A);E92K | p.Glu92Lys (c.274G>A);E92X | p.Glu92* (c.274G>T);Q98X | p.Gln98* (c.292C>T);Q98R | p.Gln98Arg (c.293A>G);P99L | p.Pro99Leu (c.296C>T);L102R | p.Leu102Arg (c.305T>G);442delA | p.Arg104Glu fs*3 (c.310delA)

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Yes

* Was a commercial kit used? *

No

For non-commercial kits, provide regions of the gene that are sequenced *

Specify Variants Detected *

(c.174_177delTAGA);306insA | p.Arg59Lysfs*10 (c.175dupA);E60K | p.Glu60Lys (c.178G>A);E60X | p.Glu60* (c.178G>T);P67L | p.Pro67Leu (c.200C>T);K75X | p.Arg75* (c.223C>T);365-366insT | p.Trp79Leufs*32 (c.233dupT);G85E | p.Gly85Glu (c.254G>A);394delTT | p.Leu88Ilefs*22 (c.262_263delTT);L88X | p.Leu88* (c.263T>A);L88X | p.Leu88* (c.263T>G);G91R | p.Gly91Arg (c.271G>A);405+1G->A | p.? (c.273+1G>A);405+3A->C | p.? (c.273+3A>C);406-2A->G | p.? (c.274-2A>G);406-1G->A | p.? (c.274-1G>A);E92K | p.Glu92Lys (c.274G>A);E92X | p.Glu92* (c.274G>T);Q98X | p.Gln98* (c.292C>T);Q98R | p.Gln98Arg (c.293A>G);P99L | p.Pro99Leu (c.296C>T);L102R | p.Leu102Arg (c.305T>G);442delA | p.Arg104Glu fs*3 (c.310delA)

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

Yes

* Was a commercial kit used? *

No

For non-commercial kits, provide regions of the gene that are sequenced *

exons 1 to 27 and at least 20 bases into the 5' and 3' ends of all introns, the CFTR poly T status and TG tract, intron 22

Extraction Method

Select an extraction method *

1. To select an extraction method, click on the magnifying glass and select a method from the search box.

2. Choose a method then click 'Select'.

3. Continue to section 1.6 for guidance on reporting pathogenic variant data.

July 2026

1.5 Specifying Variants Detected

If restrictions were placed or laboratory specific customizations were made on variants that are detectable using a primary or secondary/confirmatory method, the detected variants must be specified for each method.

The variants detected by your lab should be listed in the indicated text boxes. **Format each variant by separating each with a semicolon ";"**. Alternatively, if the variants that your lab detect are on your program's website, reference your website.

Home > Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

‡ Definition of commercial kit – A kit that has been designed by the manufacturer to sequence the CFTR gene

Method Information

Primary Method

Select a primary method *

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify variants detected: *

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.

Was a gene sequencing method used? *

No

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Agena Bioscience iPLEX Pro CFTR Panel (72 mutations)

Select an algorithm for utilization of the secondary/confirmatory method *


Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes


Specify Variants Detected *

List the variants detected by your lab-separate each variant by a semicolon ";". If the variants that your lab detect are on your program's website, you may instead list your website.


To assist with formatting the variant list, the delim.co website can be used as a tool to generate the formatted list. The tool is available at delim.co.




1. Paste the unformatted variant list in the box labeled 'Column Data Here'.




2. Select the semicolon option for the drop-down menu.



3. Select the blue right pointing arrow.



4. Copy formatted data and paste into the NSQAP CFDNAPT Portal page.



1.6 Specimen Results - Pathogenic Variant Data Entry

Navigate to the page titled 'Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)' to enter CFDNAPT pathogenic variant results including allele 1, allele 2, and clinical assessment for each specimen. Navigation details can be found in section 1.1.

Home > Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Pathogenic Variant Data

If the variant you wish to enter is not found within the searchable listing, select "other" and then enter the variant in the field that will appear when "other" is selected.

Specimen Number 20211011001	Allele 1 * 	Allele 2 * 	Clinical Assessment * 	Comments
Specimen Number 20211011002	Allele 1 * 	Allele 2 * 	Clinical Assessment * 	Comments
Specimen Number 20211011003	Allele 1 * 	Allele 2 * 	Clinical Assessment * 	Comments
Specimen Number 20211011004	Allele 1 * 	Allele 2 * 	Clinical Assessment * 	Comments
Specimen Number 20211011005	Allele 1 * 	Allele 2 * 	Clinical Assessment * 	Comments

Participating laboratories must generate and submit their own results and must not share NSQAP PT test results or specimens with any other laboratory under ANY circumstance, even if the laboratory normally sends specimens to referral laboratories for routine or confirmatory testing. If participants are found to have falsified or shared results or specimens, the NSQAP committee will convene to discuss response actions for the participant which may include termination from the program.

Use of trade names is for identification only and does not imply endorsement by the Public Health Service, the U.S. Department of Health and Human Services, or the Association of Public Health Laboratories.

Save

- Click the magnifying glass to select a variant value for 'Allele 1' and 'Allele 2' for each specimen.

Pathogenic Variant Data

If the variant you wish to enter is not found within the searchable listing, select "other" and then enter the variant in the field that will appear when "other" is selected.

Specimen Number
20211011001

Allele 1 *

Allele 2 *

Clinical Assessment *

Comments

- Search for variants using the search box. Click 'Select'.

Lookup records

Search

Display Name	Variant cDNA name	Variant protein name	Variant legacy name
No variants detected	No variants detected	No variants detected	No variants detected
G330X (p.Gly330X)	c.988G>T	p.Gly330X	G330X
1119delA (p.Gly330GluX39)	c.987delA	p.Gly330GluX39	1119delA
L320V (p.Leu320Val)	c.958T>G	p.Leu320Val	L320V
1078delT (p.Phe316LeufsX12)	c.948delT	p.Phe316LeufsX12	1078delT
G314E (p.Gly314Glu)	c.941G>A	p.Gly314Glu	G314E
F311L (p.Phe311Leu)	c.933C>G	p.Phe311Leu	F311L
F311del (p.Phe312del)	c.933 935delCTT	p.Phe312del	F311del

Pathogenic Variant Data

If the variant you wish to enter is not found within the searchable listing, select "other" and then enter the variant in the field that will appear when "other" is selected.

Specimen Number
20211011001

Allele 1 *

Allele 2 *

Clinical Assessment *

Comments

Specimen Number
20211011002

Allele 1 *

Allele 2 *

Clinical Assessment *

Comments

- Variants can be quickly located by typing the variant name in the provided search box.

Lookup records

1898

Display Name	Variant cDNA name	Variant protein name	Variant legacy name
1898+5G>T (c.1766+5G>T)	c.1766+5G>T	None	1898+5G>T
1898+3A>G (c.1766+3A>G)	c.1766+3A>G	None	1898+3A>G
1898+1G>T (c.1766+1G>T)	c.1766+1G>T	None	1898+1G>T
1898+1G>C (c.1766+1G>C)	c.1766+1G>C	None	1898+1G>C
1898+1G>A (c.1766+1G>A)	c.1766+1G>A	None	1898+1G>A

- Choose a clinical assessment code for each specimen by clicking the drop-down arrow.

Pathogenic Variant Data

If the variant you wish to enter is not found within the searchable listing, select "other" and then enter the variant in the field that will appear when "other" is selected.

Specimen Number
20211011001

Allele 1 *
No variants detect [X] [Q]

Allele 2 *
No variants detect [X] [Q]

Clinical Assessment *
[v]
Screen Negative-Normal
Screen Positive-1 or 2 variants
Assay Failure

Comments
[]

Specimen Number
20211011002

Allele 1 *
[] [Q]

Allele 2 *
[] [Q]

Clinical Assessment *
[v]

Comments
[]

- If 'Assay Failure' is chosen as the clinical assessment, choose it for both Allele 1 and Allele 2.

Lookup records

assay [Q]

✓ Display Name	Variant cDNA name ↓	Variant protein name	Variant legacy name
✓ Assay Failure	Assay Failure	Assay Failure	Assay Failure

[Select] [Cancel] [Remove value]

Pathogenic Variant Data

If the variant you wish to enter is not found within the searchable listing, select "other" and then enter the variant in the field that will appear when "other" is selected.

Specimen Number
20211011001

Allele 1 *
Assay Failure [X] [Q]

Allele 2 *
Assay Failure [X] [Q]

Clinical Assessment *
Assay Failure [v]

Comments
[]

Specimen Number
20211011002

Allele 1 *
[] [Q]

Allele 2 *
[] [Q]

Clinical Assessment *
[v]

Comments
[]

- If necessary, enter any comments into the appropriate comment box.

Pathogenic Variant Data

If the variant you wish to enter is not found within the searchable listing, select "other" and then enter the variant in the field that will appear when "other" is selected.

Specimen Number
20211011001

Allele 1 *
Assay Failure [X] [Q]

Allele 2 *
Assay Failure [X] [Q]

Clinical Assessment *
Assay Failure [v]

Comments
[]

Specimen Number
20211011002

Allele 1 *
[] [Q]

Allele 2 *
[] [Q]

Clinical Assessment *
[v]

Comments
[]

1.7 Save

1. Save all information and data by clicking the **'Save'** button located at the bottom of the page.

NOTE: All information and results must be saved at the same time. Data cannot be partially saved.

Specimen Number
20211011004

Allele 1 *
CFTRdup6b-10 (c.)

Allele 2 *
4259del5 (p.Leu13)

Clinical Assessment *
Screen Positive-1 or 2 varia

Comments

Specimen Number
20211011005

Allele 1 *
R31L (p.Arg31Leu)

Allele 2 *
Q30X (p.Gln30X)

Clinical Assessment *
Screen Negative-Normal

Comments

Participating laboratories must generate and submit their own results and must not share NSQAP PT test results or specimens with any other laboratory under ANY circumstance, even if the laboratory normally sends specimens to referral laboratories for routine or confirmatory testing. If participants are found to have falsified or shared results or specimens, the NSQAP committee will convene to discuss response actions for the participant which may include termination from the program.

Use of trade names is for identification only and does not imply endorsement by the Public Health Service, the U.S. Department of Health and Human Services, or the Association of Public Health Laboratories.

Save

2. If you attempt to save the form without entering **all required fields** you will receive an error message. Complete the missing fields and click 'Save' again.

Home > Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Cystic Fibrosis DNA Variant Detection Proficiency Testing (CFDNAPT)

Definition of commercial kit – A kit that has been designed by the manufacturer to sequence the CFTR gene

i The form could not be submitted for the following reasons:

- Select an extraction method is a required field.
- Allele 1 is a required field.
- Allele 2 is a required field.

Method Information

Primary Method

Select a primary method *

Abbott Molecular CF Genotyping Assay v3


3. After you have successfully saved your results, you will be redirected to the 'CFDNA Review/Submit Page'. See section 2 for more guidance on this page.

2. CFDNAPT Review & Submit Page

2.1 Navigation

To review and submit CFDNAPT data, navigate to the CFDNAPT program review and submit page. Access the page from the 'CFDNA Review/Submit' option on the Molecular PT landing page.

1. Click '**PT Information**' from the upper toolbar.



2. Click '**Molecular PT**' from the PT Information page.



3. Click 'CFDNA' to navigate to the Review/Submit page.

The screenshot displays four data tables arranged in a 2x2 grid. The top-right table, 'CFDNA Review/Submit', is highlighted with a blue border. All tables have a 'Name' column with a dropdown arrow and a 'Submitted By' column.

CFDNA Entry	
Name ▾	Saved By
CFDNA	

CFDNA Review/Submit		
Name ▾	Submitted By	isSubmitted
CFDNA		No

SMA Entry	
Name	Saved By
SMA	

SMA Review/Submit		
Name ▾	Submitted By	isSubmitted
SMA		No

TREC Entry	
Name ▾	Saved By
TREC	

TREC Submit/Review		
Name ▾	Submitted By	isSubmitted
TREC		Yes

2.2 Review

Navigate to the 'CFDNA Review/Submit Page' to review CFDNAPT program method information and specimen results in a read-only format. Navigation details can be found in section 2.1.

Home > CFDNAPT-Review/Submit

CFDNAPT-Review/Submit

Method Information

Primary Method

Select a primary method *

Abbott Molecular CF Genotyping Assay v3

Other-you must specify

—

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify variants detected: *

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.?

Was a gene sequencing method used? *

Yes

Was a commercial kit used? *

No

For non-commercial kits, provide regions of the gene that are sequenced *

exons 1 to 27 and at least 20 bases into the 5' and 3' ends of all introns, the CFTR poly T status and TG tract, intron 22

Secondary/Confirmatory Method

Select a secondary/confirmatory method

Agena Bioscience iPLEX Pro CFTR Panel (72 mutations)

Other-you must specify

—

Select an algorithm for utilization of the secondary/confirmatory method *

Both the primary and secondary methods are used to detect variants

Other-you must describe

—

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify Variants Detected

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.?

Was a gene sequencing method used? *

Yes

Was a commercial kit used? *

No

For non-commercial kits, provide regions of the gene that are sequenced *

exons 1 to 27 and at least 20 bases into the 5' and 3' ends of all introns, the CFTR poly T status and TG tract, intron 22

Extraction Method

Select an extraction method *

In-house alkaline lysis prep

Other-you must specify

Pathogenic Variant Data

Specimen Number

20211011001

Allele 1 *

Q1412X (p.Gln1412X)

Other Variant Detected

—

Allele 2 *

C276X (p.Cys276X)

Other Variant Detected

—

Clinical Assessment *

Screen Negative-Normal

Comments

—

Specimen Number

20211011002

Allele 1 *

849delG (p.Leu240X)

Other Variant Detected

—

Allele 2 *

D1152H (p.Asp1152His)

Other Variant Detected

—

Clinical Assessment *

Screen Negative-Normal

Comments

—

Specimen Number

20211011003

Allele 1 *

4374+1G>T (c.4242+1G>T)

Other Variant Detected

—

Allele 2 *

L1254X (p.Leu1254X)

Other Variant Detected

—

Clinical Assessment *

Screen Positive-1 or 2 variants

Comments

—

Specimen Number

20211011004

Allele 1 *

CFTRdup6b-10 (c.(743+1_744-1)_(1584+1_1585-1)dup)

Other Variant Detected

—

Allele 2 *

4259del5 (p.Leu1376SerfsX8)

Other Variant Detected

—

Clinical Assessment *

Screen Positive-1 or 2 variants

Comments

—

Specimen Number

20211011005

Allele 1 *

R31L (p.Arg31Leu)

Other Variant Detected

—

Allele 2 *

Q30X (p.Gln30X)

Other Variant Detected

—

Clinical Assessment *

Screen Negative-Normal

Comments

—

After you click submit your submission will be locked and cannot be changed. [Navigate to the CFDNA Entry Page to Make Edits](#)

1. If edits are necessary, navigate back to the CFDNA entry page and make or click the link located at the bottom of the review and submit page labeled **'Navigate to the CFDNAPT Entry Page to Make Edits'**.

Specimen Number	
20211011005	
Allele 1 *	Other Variant Detected
R31L (p.Arg31Leu)	—
Allele 2 *	Other Variant Detected
Q30X (p.Gln30X)	—
Clinical Assessment *	Comments
Screen Negative-Normal	—

After you click submit your submission will be locked and cannot be changed. [Navigate to the CFDNA Entry Page to Make Edits](#)

[Submit](#)

2. If no further edits are needed, results can be submitted by clicking the 'Submit' button. See section 2.3 for additional details.

Allele 1 *	Other Variant Detected
R31L (p.Arg31Leu)	—
Allele 2 *	Other Variant Detected
Q30X (p.Gln30X)	—
Clinical Assessment *	Comments
Screen Negative-Normal	—

After you click submit your submission will be locked and cannot be changed. [Navigate to the CFDNA Entry Page to Make Edits](#)

[Submit](#)

2.3 Submit

1. Navigate to the 'CFDNA Review/Submit Page' to submit CFDNAPT method information and data.

Home > CFDNAPT-Review/Submit

CFDNAPT-Review/Submit

Method Information

Primary Method

Select a primary method *

Abbott Molecular CF Genotyping Assay v3

Other-you must specify

—

Is your selected method a custom commercial assay OR a lab developed test OR does your lab place restrictions on a commercial assay? *

Yes

Specify variants detected: *

M1V | p.Met1Val / p.Met1? (c.1A>G);Q2X | p.Gln2* (c.4C>T);S4X | p.Ser4* (c.11C>A);S13F | p.Ser13Phe (c.38C>T);182delT | p.Phe17Serfs*8 (c.50delT);L15P | p.Leu15Pro (c.44T>C);185+1G->T | p.? (c.53+1G>T);W19X | p.Trp19* (c.57G>A);G27R | p.Gly27Arg (c.79G>A);G27X | p.Gly27* (c.79G>T);Q30X | p.Gln30* (c.88C>T);Q39X | p.Gln39* (c.115C>T);A46D | p.Ala46Asp (c.137C>A);296+1G->A | p.? (c.164+1G>A);296+1G->T | p.? (c.164+1G>T);296+2T->C | p.? (c.164+2T>C);296+3insT | p.? (c.164+4dupT);297-3C->T | p.?

Was a gene sequencing method used? *

Yes

2. After reviewing the CFDNA review and submit page, click on the '**Submit**' button located at the bottom of the page.


Allele 1 *	Other Variant Detected
R31L (p.Arg31Leu)	—
Allele 2 *	Other Variant Detected
Q30X (p.Gln30X)	—
Clinical Assessment *	Comments
Screen Negative-Normal	—

After you click submit your submission will be locked and cannot be changed. [Navigate to the CFDNA Entry Page to Make Edits](#)


Submit

3. You will be prompted to confirm that you are ready to submit. Click '**Ok**' to confirm and submit your CFDNAPT results.

NOTE: You are only allowed to submit your results **ONCE**. You must review and confirm your entered information is accurate **BEFORE** submitting.



4. After submitting you will be directed to a confirmation page.




5. Once your CFDNAPT results are submitted you will no longer be able to access the 'CFDNA Entry' page. You can view your submitted data in a read-only format by accessing the review and submit page (see sections 2.1 and 2.2).

2.4 Save Data – PDF Format

Submitted data can be saved in a PDF format by using the ‘Save a PDF’ function included in your web browser.

Note: The location and appearance of this functionality will vary depending on the web browser being used.

1. Navigate to the review and submit page as described in section 2.1.




The screenshot displays a web interface for reviewing and submitting data. It is organized into a grid of six tables, grouped by method: CFDNA, SMA, and TREC. Each method has an 'Entry' table and a 'Review/Submit' table. The 'CFDNA Review/Submit' table is highlighted with a blue border.

CFDNA Entry		CFDNA Review/Submit		
Name ↑	Saved By	Name ↑	Submitted By	isSubmitted
CFDNA		CFDNA		No


SMA Entry		SMA Review/Submit		
Name	Saved By	Name ↑	Submitted By	isSubmitted
SMA		SMA		No

TREC Entry		TREC Submit/Review		
Name ↑	Saved By	Name ↑	Submitted By	isSubmitted
TREC		TREC		Yes


2. Locate the “Print” function on your web browser.




3. Select 'Save as PDF'.



4. Select 'Landscape' as the layout choice.



5. Select 'More Settings'.



6. Adjust the scale percentage to 60%.

The screenshot shows the 'CFDNAPT-Review/Submit' form. On the left, a sidebar titled 'Print' is open, showing settings for 'Total: 4 pages'. The 'Scale (%)' is set to 60, which is highlighted with a red box. Other settings include 'Paper size: Letter', 'Pages per sheet: 1', and 'Margins: Default'. The 'Save' button is highlighted in blue. The main form area shows 'Method Information' with a 'Primary Method' section containing a list of variants and a 'Secondary/Confirmatory Method' section.

7. Select 'Save' to save the pdf file to your local drive's folder of choice.

This screenshot is identical to the previous one, showing the 'CFDNAPT-Review/Submit' form with the 'Print' sidebar open. The 'Scale (%)' is still 60. The 'Save' button in the sidebar is now highlighted in blue, indicating it should be clicked to save the PDF file.